Overview

HIST2H3D is altered in 1.02% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, prostate adenocarcinoma, invasive breast carcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

The most common alterations in HIST2H3D are HIST2H3D Amplification (0.95%), HIST2H3D A136V (0.01%), HIST2H3D Loss (0.01%), HIST2H3D R132H (0.01%), and HIST2H3D A115V (0.01%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.